Drastic shift from positive to negative estrogen effect on bone morphogenetic protein signaling in pulmonary arterial endothelial cells under hypoxia

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2119-2126

  Ichimori, Hiroaki ^a   Kogaki, Shigetoyo ^a   Takahashi, Kunihiko ^a   Ishida, Hidekazu ^a   Narita, Jun ^a   Nawa, Nobutoshi ^a   Baden, Hiroki ^a   Uchikawa, Toshiki ^a   Okada, Yoko ^a   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone morphogenetic protein; Estrogen; Hypoxia inducible factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CYCLOHEXIMIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF DIFFERENTIATION 1; LUCIFERASE; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; ANTIESTROGEN; HIF1A PROTEIN, HUMAN; PROTEIN SYNTHESIS INHIBITOR;

ARTICLE; CELL CULTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOPRECIPITATION; LUNG ARTERY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL HYPOXIA; DRUG EFFECTS; METABOLISM; MORTALITY; PATHOLOGY; PULMONARY ARTERY;

BONE MORPHOGENETIC PROTEINS; CELL HYPOXIA; CELLS, CULTURED; CYCLOHEXIMIDE; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTEIN SYNTHESIS INHIBITORS; PULMONARY ARTERY; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84880803378     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0997     Document Type: Article

References (37)

1. SPimonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classifcation of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
2. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
3. Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, Inai K, et al. Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. Circ J 2012; 76: 1501-1508.
4. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, Imamura S, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72: 127-133.
5. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46: 331-337.
6. International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
7. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-132.
8. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745.
9. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678.
10. Austin ED, Loyd JE, Phillips JA 3rd. Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 386-398.
11. Rosenzweig EB, Morse JH, Knowles JA, Chada KK, Khan AM, Roberts KE, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27: 668-674.
12. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol 2006; 35: 468-471.
13. Lahm T, Crisostomo PR, Markel TA, Wang M, Weil BR, Novotny NM, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: Potential new clinical implications for an old hormone. Crit Care Med 2008; 36: 2174-2183.
14. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
15. Takahashi K, Kogaki S, Matsushita T, Nasuno S, Kurotobi S, Ozono K. Hypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cell. Pediatr Res 2007; 61: 392-397.
16. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1340-1348.
17. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specifc markers: Evidence for a dynamic and heterogeneous process of pulmonary endo-thelial cell growth. Am J Pathol 1999; 155: 411-419.
18. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterio-scler Thromb Vasc Biol 2007; 27: 1072-1078.
19. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-374.
20. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hy-poxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-4163.
21. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, et al. Cell type-specifc regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074-1081.
22. Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R. Identifcation of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 2002; 7: 949-960.
23. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-731.
24. Kawai M, Namba N, Mushiake S, Etani Y, Nishimura R, Makishima M, et al. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway. J Mol Endocrinol 2007; 38: 19-34.
25. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
26. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
27. Yamamoto T, Saatcioglu F, Matsuda T. Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 2002; 143: 2635-2642.
28. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003; 100: 1034-1039.
29. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, et al. First evidence supporting a potential role for the BMP/ SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 2005; 206: 366-376.
30. Fijalkowska I, Xu W, Comhair SA, Janocha AM, Mavrakis LA, Krishnamachary B, et al. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 2010; 176: 1130-1138.
31. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hy-poxic responses. J Cell Sci 2001; 114: 4051-4061.
32. Cho J, Kim D, Lee S, Lee Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 2005; 19: 1191-1199.
33. Masuda H, Otsuka F, Matsumoto Y, Takano M, Miyoshi T, Inagaki K, et al. Functional interaction of fbroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation. Mol Cell Endocrinol 2011; 343: 7-17.
34. Ito I, Hanyu A, Wayama M, Goto N, Katsuno Y, Kawasaki S, et al. Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 2010; 285: 14747-14755.
35. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in oestrogen metabolism: Implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009; 34: 1093-1099.
36. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011; 90: 373-382.
37. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specifc to females. Respir Res 2011; 12: 159.